Recent Advances in Management of Diabetic Macular Edema

Author(s): Koushik Tripathy, Yog Raj Sharma, Karthikeya R, Rohan Chawla, Varun Gogia, Subodh Kumar Singh, Pradeep Venkatesh, Rajpal Vohra

Journal Name: Current Diabetes Reviews

Volume 11 , Issue 2 , 2015

Become EABM
Become Reviewer
Call for Editor


Diabetic macular edema (DME) is the leading cause of moderate vision loss in diabetics. Modalities to image and monitor DME have evolved much in the last decade. Systemic control is the most important part of management. Available ocular management options include intravitreal antivascular endothelial growth factor (anti-VEGF) agents, laser, steroids (intravitreal or peribulbar), vitrectomy, topical medications and others. Anti-VEGF agents are increasingly being used in clinical practice with good clinical response and are currently the preferred mode of treatment worldwide.

Keywords: Aflibercept, aspirin, bevacizumab, diabetic retinopathy, glitazones, iluvien, i-vation, mecamylamine, medidur, midostaurin, nepafenac, ozurdex, PASCAL, ranibizumab, retisert, ruboxistaurin, selective retina therapy (SRT), sorbinil, subthreshold micropulse diode laser photocoagulation, VEGF.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 13 April, 2015
Page: [79 - 97]
Pages: 19
DOI: 10.2174/1573399811999150324120640
Price: $65

Article Metrics

PDF: 71